Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system (the body’s natural defenses).
Tremelimumab is engineered to attach to and prevent CTLA-4 from functioning, a protein that modulates the response of T cells, an integral part of the immune system.